SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY THE NMPA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that LM-24C5 "CEACAM5/4-1BB bispecific antibody", an innovative drug independently developed by LaNova Medicines Limited ("**LaNova Medicines**", a wholly-owned subsidiary of the Group), has received the clinical trial approval from the National Medical Products Administration (NMPA) of China for conducting Phase II clinical trials in patients suffering CEACAM5-positive advanced solid tumors in combination with other anti-tumor drugs.

CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) is highly expressed in various types of solid tumors, including non-small cell lung cancer, colorectal cancer, gastric cancer, and other cancers, which render it a highly promising target of the treatment for tumors[1]. LM-24C5 is a bispecific antibody developed by LaNova Medicines based on the conditionally activated 4-1BB platform, which can specifically redirect immune cells to the tumor microenvironment by specifically binding them to CEACAM5 on the surface of tumour cells and 4-1BB on the surface of immune cells, thereby activating and enhancing their anti-tumor activity. The unique structure of LM-24C5 enables the optional activation of the 4-1BB signaling pathway with CEACAM5-dependent approaches, while avoiding the toxicity risks associated with non-specific activation of the peripheral immune system.

Preclinical studies have shown that LM-24C5 can induce durable anti-tumor immune memory, and exhibits synergistic effects when administered in combination with other immunotherapeutic agents, thus indicating its potential to become the First-in-Class immunotherapy. Currently, LM-24C5 is undergoing Phase I/II clinical trials in the United States.

Source:

[1] Clin Cancer Res; 26(24) December 15, 2020; Clin Cancer Res. 2021 March 01; 27(3): 759–774; The Human Protein Atlas

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 7 August 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.